Evidence & Access
Australia Naltrexone PBS Check: Item 8370M and 2026 Co-payments
PBS item 8370M covers naltrexone 50 mg tablets; 2026 maximum co-payments are $25 general and $7.70 concession.
2 minute read
Naltrexone Guides
Dated evidence reviews, registry checks, and treatment explainers that show what the sources establish—and what remains uncertain.
Latest Guides
Evidence & Access
Naltrexone and Liver Disease: What Current Evidence Shows
Observational studies are reassuring in many patients with liver disease and cirrhosis, but they do not make naltrexone risk-free or settle every decompensated-liver scenario.
3 minute read
Evidence & Access
New Zealand Naltrexone Funding: June 2026 PHARMAC Check
Naltraccord 50 mg is fully subsidised under SA1408, while pharmacy charges and GP fees remain separate.
2 minute read
Evidence & Access
Naltrexone During Pregnancy and Breastfeeding: What We Know
Human pregnancy evidence remains limited; breastfeeding transfer appears low in one published case. Decisions require individual specialist assessment.
3 minute read
Evidence & Access
Singapore Naltrexone Check: Contrave Is Registered—What About 50 mg?
Singapore's official formulary confirms Contrave, while current standalone 50 mg naltrexone supply and price remain unverified.
2 minute read
Evidence & Access
UAE Naltrexone Registry Check: What Is Actually Listed?
A dated check of the UAE drug directory: Contrave is active, standalone naltrexone was not found, and DHA guidance still recognises naltrexone clinically.
2 minute read
Evidence & Access
Naltrexone vs Acamprosate and Disulfiram
Naltrexone, acamprosate, and disulfiram have different goals, contraindications, and evidence. There is no universal best medicine.
3 minute read
Evidence & Access
Contrave for Weight Management: What the Trials Establish
Contrave produced more weight loss than placebo in pivotal trials, but tolerability, discontinuation, and unresolved cardiovascular outcomes matter.
3 minute read
Evidence & Access
Targeted Naltrexone in Asia-Pacific: What Access Evidence Shows
Targeted naltrexone has trial evidence, but local access depends first on whether standalone naltrexone is marketed and whether a clinician supports the protocol.
3 minute read